The Latest

Type image caption here (optional)Dr. PagdinDear Colleagues,Innovation in peptide research is driven by collaboration. At CPRS, we believe that sharing knowledge and data accelerates discovery and ensures safe, effective therapies for patients across North America and Canada.Highlights from the AMMG Conference: Building Bridges for Peptide ResearchAt the recent AMMG conference, Dr. Pagdin had an inspiring experience connecting with industry leaders and discussing the exciting prospect of establishing a North American Research Society. The goal is to foster greater collaboration across the continent — linking efforts in the U.S. and Canada to advance peptide science. A key focus is securing IRB approval that covers both countries, with options like Advarra offering streamlined pathways.Robust data collection remains vital to accelerating discoveries in peptide research. We look forward to continuing these conversations and exploring new partnerships that will drive innovation and improve patient outcomes throughout North America!CPRS Focus Areas Include:Clinical data collection on peptide useStandardizing treatment protocolsExploring new peptide applications in autoimmunity, orthopedics, dermatology, and moreSupporting hypothesis-driven research initiativesHow Can You Contribute?CPRS offers a platform for clinicians and researchers to collaborate on pilot studies, share case reports, and participate in consensus-building efforts. Our partnerships with organizations like RegenMed enable us to gather real-world evidence that informs best practices.Become a MemberMembership with CPRS provides access to exclusive resources, networking opportunities, and the chance to influence the future of peptide medicine. Visit our website to learn more and get involved.Special Membership Offer!We’re excited to share some great news! Enjoy $100 off your CPRS membership with the code COAM2025 through the end of December. Regularly priced at $500/year,our membership provides access to a wealth of valuable content on peptides, as well as our innovative PROM tools. Plus, you have the opportunity to share in licensing fees for any data you contribute.Check it out at www.cpr-society.com and please forward this to any colleagues who may be interested.Let’s work together to redefine what's possible with peptide science.Best regards,Dr. Grant PagdinCanadian Peptide Research Society

Why unverified data will become the next malpractice. The New Chain of CausationFor centuries, malpractice was simple: a human erred, a patient suffered, a court assigned fault. AI has shattered that chain. When a model misdiagnoses, who is responsible — the developer, the clinician, or the data? In truth, liability now begins upstream. Every data omission, every mislabeled record, every untracked transformation embeds risk directly into the algorithm. The model may carry a hospital’s logo, but the error belongs to every unseen hand that shaped the data beneath it. The modern question is not “Who pressed run?” but “Who governed what ran?” When Data Becomes a DefectCourts and regulators are already redefining causation in algorithmic contexts. In traditional tort law, liability required a negligent act; in the age of automation, defective data may itself constitute negligence. If an institution deploys a clinical model trained on unverifiable inputs, it is effectively practicing with a contaminated instrument. The injury may be digital, but the duty of care is physical. “Garbage in, garbage out” has evolved into “garbage in, liability out.” The Regulator’s DilemmaRegulators once inspected devices; now they must inspect datasets. But inspection requires something most healthcare data still lacks: provenance. Without immutable lineage — a record of who entered what, when, and under which protocol — oversight becomes impossible. Most existing EHR-derived datasets fail this test. They are statistical fossils: layers of undocumented adjustments and missing context. A regulator can only validate what is visible. Provenance transforms visibility from metaphor into metric. Federation as Liability Containment Centralized data aggregation concentrates not only power but blame. A federated model distributes both. By keeping data at its source and standardizing governance locally, Circle Datasets minimize institutional exposure. Each node retains control, applies harmonized protocols, and contributes only validated derivatives — ensuring that every partner’s risk remains proportional to its stewardship. This is not decentralization for convenience; it is decentralization for indemnification. The Economics of Verification Liability follows opacity the way infection follows contamination. The more opaque the pipeline, the higher the premium — whether in insurance, compliance cost, or reputational risk. Verified datasets reduce that burden by transforming uncertainty into auditable structure. When governance is embedded in the data itself, regulators shift from detectives to auditors; oversight becomes confirmation rather than investigation. The cost of verification up front becomes the price of immunity later. Redefining Due Diligence Investors and insurers will soon demand proof of data integrity as a condition of participation. Auditable provenance will move from ethical virtue to commercial requirement — the new “clean title” of digital assets. Hospitals will ask vendors not just “What does your model do?” but “Show us your lineage chain.” In discovery, legal teams will request data passports, not just training logs. Due diligence will no longer mean reviewing documentation; it will mean verifying immutability. Toward a Liability-Resilient Ecosystem A liability-resilient AI ecosystem is one where every prediction carries a traceable ancestry, every dataset has a custodial signature, and every model can be re-audited against its inputs. Federated Circle Datasets make this possible — not by eliminating risk, but by binding responsibility to evidence. They turn uncertainty into structure, structure into accountability, and accountability into trust. The future of medical AI will belong to systems that can not only think, but testify. Selected ReferencesRegenMed (2025). Circle Datasets Meet the Challenges of Federated Healthcare Data Capture. White Paper. Price, W. N., Cohen, I. G. (2019). Privacy in the Age of Medical Big Data. Nature Medicine. OECD (2024). Trustworthy AI in Healthcare: Data Governance and Accountability Frameworks. European Commission (2024). AI Liability Directive: Implications for Health Data Use.

The University of Wisconsin/Madison enjoys a strong global reputation for medical discovery as well as computer science – a powerful match for RegenMed’s value propositions. We were therefore honored this past summer to be invited to join GE Healthcare, Google, Qualcomm (among others) in designing and supporting Capstone projects undertaken by graduating data science engineers. This past semester’s impressive work by two separate RegenMed teams was presented on December 1. Both projects – comprising polished front-end and back-end coding – will meaningfully strengthen patient outcomes survey completion on our patented Benchmarc™ platform. They will also increase patients’ visibility into their clinical progress on an individual and cohort basis. Next semester’s Capstone teams will build on this foundation, as we evolve Benchmarc™ into a best-in-class patient-facing platform (i) incentivizing them to provide their key clinical outcomes data, (ii) enabling them to see the impact it makes on their care as well as patients like them, and (iii) provides concrete benefits for their important contributions in advancing evidence-based standards of care.

Why the next era of healthcare AI will be defined by data credibility, not computational power. The Hype Cycle Meets the Hospital Floor Over the past five years, AI has transformed from promise to ubiquity. Clinical imaging models outperform residents in narrow benchmarks, predictive algorithms forecast patient outcomes, and language models generate plausible medical documentation at scale. Yet when these systems reach production — when they leave the lab and touch real patients — performance drops sharply. Context changes, populations differ, workflows interfere, and confidence intervals collapse. AI in healthcare is experiencing its first systemic reckoning: the realization that intelligence without integrity cannot scale. Data: The Unspoken Weak Link Most AI failures in medicine trace not to models, but to data. Training sets are often: Non-representative (biased toward specific populations or institutions). Non-longitudinal (lacking follow-up, preventing learning from outcomes). Non-verifiable (missing provenance, making errors invisible). As a result, algorithms perform well in validation studies but poorly in the wild. The problem isn’t overfitting — it’s overconfidence in datasets that can’t be proven. For an industry regulated by reproducibility, the current data ecosystem is not merely inefficient; it’s noncompliant. The Regulatory CrossroadsRegulators are catching up quickly. The FDA, EMA, and Health Canada have all issued guidance emphasizing Good Machine Learning Practice (GMLP), model monitoring, and dataset auditability. Soon, the question won’t be “does the model work?” but “can you prove how it learned?” This shift places healthcare AI on the same trajectory as clinical research: evidence-based, auditable, and transparent by default. Without verifiable data provenance, no amount of algorithmic sophistication will meet regulatory thresholds for safety and accountability. The Economic Cost of Fragile AIFor investors and health systems, weak data governance translates directly into financial risk. AI pilots stall, compliance reviews expand, and insurers hesitate to reimburse outcomes tied to unverifiable models. A Deloitte survey in 2025 found that over 60% of healthcare AI projects fail to reach sustained deployment — not for lack of accuracy, but for lack of defensible evidence. The cost of mistrust compounds faster than the cost of computation. Every failed validation erodes institutional confidence, delays adoption, and inflates oversight costs. The market’s next inflection point will belong to platforms that can prove reliability, not just demonstrate it. Toward Verifiable Intelligence The reckoning now underway is healthy — it signals maturity. Healthcare AI is moving from experimentation to engineering, from enthusiasm to evidence, from code to compliance. Circle’s architecture represents this transition: an ecosystem where every dataset is sourced, structured, and validated through continuous observational protocols. This turns data from a liability into an asset — a reusable, regulator-ready foundation for learning systems that can evolve safely and transparently. Strategic Outcome The AI reckoning is not a collapse; it’s a correction. Just as clinical research evolved from anecdote to trial, healthcare AI must evolve from black box to verified instrument. Those who invest early in verifiable data architectures — systems that record consent, lineage, and outcomes automatically — will own the infrastructure of the next generation of medical intelligence. In the coming years, the differentiator in healthcare AI will not be algorithmic sophistication, but the credibility of the data that trains it. Key Takeaways ‍

The PremiseThe modern research enterprise has become an industry in every structural sense — an apparatus of production, optimization, and throughput. What once resembled a guild of discovery now mirrors a supply chain. Ideas move through the system like commodities: designed, refined, and delivered under pressure to meet output quotas. Laboratories have become factories of “deliverables,” and scientists, line workers in a cognitive assembly line. This industrial model did not arise by conspiracy but by drift. As public funding tightened and accountability rose, universities adopted corporate logics of efficiency and performance. The scientist became a manager of metrics. Inquiry, once an act of reflection, became an act of compliance. The DistortionIndustrialization distorts inquiry in predictable ways. The demand for volume fragments attention: large teams produce countless substudies to satisfy contractual milestones. Methodological creativity declines as workflows standardize. The grant proposal replaces the hypothesis as the true object of innovation. Researchers learn to design not for discovery, but for deliverability — for the optics of progress that can be audited, reported, and scaled. Even language succumbs to bureaucracy. Ideas are described in terms of pipelines, portfolios, and key performance indicators. The lexicon of curiosity is replaced by that of logistics. What cannot be quantified cannot be justified. The ConsequenceIndustrialized inquiry produces safe science — technically competent, procedurally correct, and spiritually vacant. Questions that might challenge paradigms are deferred as “too risky.” Senior investigators manage portfolios; junior scientists execute tasks. Curiosity, the irreducible engine of progress, is crowded out by administrative survival. The result is a paradox: we have never produced more research, yet we understand less. The culture of production turns failure — once the most instructive outcome in science — into a liability. To admit error is to jeopardize funding; to question orthodoxy is to endanger employment. The factory floor tolerates no deviation from the plan. The Way ForwardRepairing this industrial architecture requires restoring the craft of science. Institutions must decouple intellectual risk from professional peril, rewarding exploration rather than compliance. Funding mechanisms should privilege depth over breadth and support replication as creative labor, not clerical duty. Above all, research must reclaim its artisan ethos — the deliberate, reflective, human scale of work. Inquiry cannot be mass-produced; its essence lies in attention, not acceleration. ReferencesRegenMed (2025). "Genuine Medical Research Has Lost Its Way." White Paper, November 2025.Sarewitz, D. (2016). Saving Science. The New Atlantis, 49, 4–40. Stephan, P. (2012). How Economics Shapes Science. Harvard University Press. Mirowski, P. (2011). Science-Mart: Privatizing American Science. Harvard University Press. Edwards, M. A., & Roy, S. (2017). Academic Research in the 21st Century: Maintaining Scientific Integrity in a Climate of Perverse Incentives and Hypercompetition. Environmental Engineering Science, 34(1), 51–61. Collini, S. (2012). What Are Universities For? Penguin Books.